|
KMID : 1142020200550000063
|
|
Blood Research
2020 Volume.55 No. 0 p.63 ~ p.71
|
|
|
Extranodal NK/T cell lymphoma
|
|
Jeong Seong-Hyun
|
|
|
Abstract
|
|
|
|
Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a distinct subtype of Non-Hodgkin’s lymphoma mainly involving the nasal area. Since the entity was first recognized, treatment strategies have been evolving from anthracycline-based chemotherapy and radiotherapy to L-asparaginase containing regimens and recently immune checkpoint inhibitors. With the currently used combined chemotherapy and radiotherapy, more than 70% of patients with localized disease can be cured. L-asparaginase containing regimens have significantly improved treatment outcomes among patients with advanced disease. However, the treatment outcomes of patients with disease refractory to L-asparaginase containing regimens or who experience recurrence remain poor. In this article, we cover the current treatments for ENKTL and emerging treatment approaches.
|
|
|
KEYWORD
|
|
|
Extranodal natural killer/T cell lymphoma, ENKTL, Non-Hodgkin’s lymphoma, Immunotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|